SCHEDULE 13G: L1 Capital Global Opportunities Master Fund Discloses 6.21% Stake in Aptevo Therapeutics Inc.

L1 Capital Global Opportunities Master Fund, Ltd. has reported a 6.21% beneficial ownership stake in Aptevo Therapeutics Inc., holding 200,000 shares of common stock.

Summary

• L1 Capital Global Opportunities Master Fund, Ltd., a Cayman Islands-based entity, has filed a Schedule 13G indicating beneficial ownership of Aptevo Therapeutics Inc. common stock.
• The fund beneficially owns 200,000 shares of Aptevo Therapeutics Inc. common stock.
• This ownership represents 6.21% of the total common stock outstanding.
• The percentage is calculated based on 3,223,214 common shares outstanding immediately after a recent offering, as per the Issuer's Prospectus Supplement filed on April 4, 2025.
• The fund also holds 400,000 Warrants, which are subject to a 4.99% beneficial ownership limitation and are not included in the reported 200,000 shares.
• The filing states that the securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance, though the investment itself could be seen as a positive signal of investor interest.

Positives

• Indicates investor interest in Aptevo Therapeutics Inc. from L1 Capital Global Opportunities Master Fund, Ltd.
• The acquisition of a 6.21% stake by a global opportunities fund suggests a belief in the company's potential.

Future Outlook

This Schedule 13G filing is a disclosure of current ownership and does not contain forward-looking statements or guidance regarding Aptevo Therapeutics Inc.'s future performance or strategic outlook.

Management Comments

• The filing includes a certification by David Feldman, Director of L1 Capital Global Opportunities Master Fund, Ltd., stating that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

This filing indicates an investment by a global opportunities fund in Aptevo Therapeutics Inc., a company likely operating in the biotechnology or pharmaceutical sector given its name. Such investments reflect investor confidence in specific companies within the broader healthcare or life sciences industry, rather than general industry trends.

Comparison to Industry Standards

• This document is a standard beneficial ownership disclosure (Schedule 13G) and does not provide financial or operational results for comparison against industry benchmarks or specific comparable companies/projects. It solely reports an investment fund's stake in Aptevo Therapeutics Inc.

Stakeholder Impact

• Shareholders: The disclosure of a significant ownership stake by an institutional investor may influence market perception and potentially share price.
• Management: Awareness of a new significant shareholder may influence future engagement or strategic considerations.

Key Dates

Keywords

Aptevo Therapeutics Inc., L1 Capital Global Opportunities Master Fund, Schedule 13G, Beneficial Ownership, Common Stock, Equity Stake, Investment Fund, Biotechnology, Pharmaceuticals, SEC Filing